Authors
Dominic Marcel Alfonso, Jenica Clarisse Sy, Mary Christie Palabrica
Published in
Cardiovascular drugs and therapy. Jul 15, 2026. Epub Jul 15, 2026.
Abstract
Heart failure remains a major cause of morbidity and mortality despite contemporary guideline-directed therapy, highlighting the need for additional therapeutic strategies, particularly across heterogeneous heart failure phenotypes. The apelin-Elabela-APJ axis has emerged as a biologically relevant pathway because it influences cardiac contractility, vascular tone, endothelial signalling, metabolism, and remodelling through mechanisms distinct from conventional neurohormonal targets. In this review, we examine the molecular biology of apelin, Elabela, and APJ, and critically appraise the preclinical and clinical evidence across heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, pulmonary arterial hypertension, and related cardiomyopathic states. Although experimental data and early haemodynamic studies support potential therapeutic relevance, recent setbacks with orally active APJ agonists highlight important translational challenges, including pharmacokinetic constraints, altered receptor biology in advanced disease, signalling complexity, and limited phenotypic stratification. We also discuss key research gaps and future directions, including biomarker standardisation, more human-relevant translational models, and endotype-informed trial design, that may help clarify whether apelin-targeted strategies have value in selected heart failure settings.
PMID:
42455245
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0